A systematic review of 30 RCTs assessed efficacy and long-term side effects of medications used in the treatment of obesity. It is a systematic review of 30 RCTs with a total of over 16,000 patients. To be included in the review trials had to have tested an anti-obesity drug versus placebo for one year. In particular: 16 studies in which it was tested orlistat, which has been used 10 in the sibutramine and 4 with rimonabant. The follow-up study ranged from a minimum of one year to a maximum of four. The
pharmacies, compared with placebo, lead to a reduction in body weight that is quantifiable, on average, 2.9 kg for orlistat, 4.2 kg in sibutramine and rimonabant by 4.7 kg. Additionally, both rimonabant
that orlistat reduced the risk of developing diabetes, improved blood glucose and glycohemoglobin in patients already diabetic, reduced the total cholesterol and blood pressure.
Among the side effects reported by the review stand for those of gastrointestinal orlistat, those psychiatric (depression) for rimonabant or cardiovascular (increased blood pressure and heart rate) for sibutramine.
The authors conclude that orlistat, sibutramine and rimonabant modestly reduce weight but have different effects on cardiovascular risk and specific side effects.
Source:
Rucker D, Padwal R, Li SK et al. Long-term Pharmacotherapy for obesity and overweight metanalysis updated. BMJ 2007 Dec 8; 335:1194-1199.
0 comments:
Post a Comment